{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:01:23Z","timestamp":1791000083194,"version":"4.1.0"},"reference-count":41,"publisher":"Microbiology Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12,1]]},"abstract":"<jats:p>The antibody responses elicited by immunization of humans with vaccinia virus (VACV) strains Lister, Dryvax and NYVAC have been determined and compared. Neutralizing antibodies against intracellular mature virus (IMV) and extracellular enveloped virus (EEV), and binding antibody titres (ELISA) against the EEV protein B5, the IMV proteins A27 and H3, and VACV-infected cell lysate were measured. Lister and Dryvax induced broadly similar antibody titres, consistent with the fact that these vaccines each protected against smallpox. In contrast, antibody titres induced by NYVAC were significantly lower than those induced by both Lister and Dryvax. Moreover, there were qualitative differences with NYVAC-immunized subjects failing to induce A27-specific antibodies. These observations suggest that although NYVAC is a safer VACV strain, it does not induce an optimal VACV-specific antibody response. However, NYVAC strains engineered to express antigens from other pathogens remain promising candidate vaccines for immunization against other diseases.<\/jats:p>","DOI":"10.1099\/vir.0.2008\/004440-0","type":"journal-article","created":{"date-parts":[[2008,11,13]],"date-time":"2008-11-13T19:43:46Z","timestamp":1226605426000},"page":"2992-2997","source":"Crossref","is-referenced-by-count":42,"title":["Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax"],"prefix":"10.1099","volume":"89","author":[{"given":"Claire M.","family":"Midgley","sequence":"first","affiliation":[{"name":"Department of Virology, Faculty of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike M.","family":"Putz","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan N.","family":"Weber","sequence":"additional","affiliation":[{"name":"Division of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Virology, Faculty of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1016\/j.vaccine.2004.10.052","article-title":"Reactions to small pox vaccine in naive and previously-vaccinated individuals","volume":"23","author":"Auckland","year":"2005","journal-title":"Vaccine"},{"key":"R2","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.vaccine.2008.03.083","article-title":"EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium","volume":"26","author":"Bart","year":"2008","journal-title":"Vaccine"},{"key":"R3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","article-title":"Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin","volume":"325","author":"Bell","year":"2004","journal-title":"Virology"},{"key":"R4","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R5","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/JVI.02244-07","article-title":"Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine","volume":"82","author":"Benhnia","year":"2008","journal-title":"J Virol"},{"key":"R6","first-page":"86","article-title":"Differences between extracellular and intracellular forms of poxvirus and their implications","volume":"16","author":"Boulter","year":"1973","journal-title":"Prog Med Virol"},{"key":"R7","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J Virol"},{"key":"R8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01706-07","article-title":"Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax","volume":"82","author":"Davies","year":"2008","journal-title":"J Virol"},{"key":"R9","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1086\/378518","article-title":"Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques","volume":"188","author":"Edghill-Smith","year":"2003","journal-title":"J Infect Dis"},{"key":"R10","volume-title":"Smallpox and its Eradication","author":"Fenner","year":"1988"},{"key":"R11","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.vaccine.2007.12.059","article-title":"Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine","volume":"26","author":"Ferrier-Rembert","year":"2008","journal-title":"Vaccine"},{"key":"R12","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.78.19.10230-10237.2004","article-title":"Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions","volume":"78","author":"Fogg","year":"2004","journal-title":"J Virol"},{"key":"R13","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1001\/jama.289.24.3295","article-title":"Response to smallpox vaccine in persons immunized in the distant past","volume":"289","author":"Frey","year":"2003","journal-title":"JAMA"},{"key":"R14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0140-6736(05)70234-8","article-title":"Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial","volume":"365","author":"Greenberg","year":"2005","journal-title":"Lancet"},{"key":"R15","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/nm917","article-title":"Duration of antiviral immunity after smallpox vaccination","volume":"9","author":"Hammarlund","year":"2003","journal-title":"Nat Med"},{"key":"R16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20071331","article-title":"An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses","volume":"205","author":"Harari","year":"2008","journal-title":"J Exp Med"},{"key":"R17","first-page":"87","article-title":"Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Listre strain","volume-title":"Vaccinia Viruses as Vectors for Vaccine Antignens","author":"Hashizume","year":"1985"},{"key":"R18","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.177.4.2552","article-title":"Subunit recombinant vaccine protects against monkeypox","volume":"177","author":"Heraud","year":"2006","journal-title":"J Immunol"},{"key":"R19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"key":"R20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0042-6822(02)00038-7","article-title":"Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates","volume":"306","author":"Hooper","year":"2003","journal-title":"Virology"},{"key":"R21","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J Virol"},{"key":"R22","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1086\/423848","article-title":"Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination","volume":"190","author":"Kennedy","year":"2004","journal-title":"J Infect Dis"},{"key":"R23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0264-410X(97)00265-X","article-title":"Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates","volume":"16","author":"Konishi","year":"1998","journal-title":"Vaccine"},{"key":"R24","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1128\/JVI.65.10.5631-5635.1991","article-title":"The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals","volume":"65","author":"Lai","year":"1991","journal-title":"J Virol"},{"key":"R25A","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1099\/vir.0.80660-0","article-title":"An investigetion of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model","volume":"86","author":"Law","year":"2005","journal-title":"J Gen Virol"},{"key":"R25","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","article-title":"Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge","volume":"79","author":"Lustig","year":"2005","journal-title":"J Virol"},{"key":"R26","first-page":"24","article-title":"Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl Bakteriol [Orig]"},{"key":"R27","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2008.02.072","article-title":"EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone","volume":"26","author":"McCormack","year":"2008","journal-title":"Vaccine"},{"key":"R28","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1128\/JVI.02108-05","article-title":"Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene","volume":"80","author":"Najera","year":"2006","journal-title":"J Virol"},{"key":"R29","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1086\/515331","article-title":"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"177","author":"Ockenhouse","year":"1998","journal-title":"J Infect Dis"},{"key":"R30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","article-title":"Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals","volume":"25","author":"Parrino","year":"2007","journal-title":"Vaccine"},{"key":"R31","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1016\/j.vaccine.2004.02.034","article-title":"Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB\/c mice from a lethal intranasal poxvirus challenge","volume":"22","author":"Pulford","year":"2004","journal-title":"Vaccine"},{"key":"R32","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1099\/vir.0.81265-0","article-title":"Prevalence of antibodies to Vaccinia virus after smallpox vaccination in Italy","volume":"86","author":"Putz","year":"2005","journal-title":"J Gen Virol"},{"key":"R33","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/nm1457","article-title":"Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination","volume":"12","author":"Putz","year":"2006","journal-title":"Nat Med"},{"key":"R34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1084\/jem.54.4.453","article-title":"Cultivation of vaccinia virus for Jennerian prophylaxis in man","volume":"54","author":"Rivers","year":"1931","journal-title":"J Exp Med"},{"key":"R35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nri845","article-title":"Smallpox: anything to declare?","volume":"2","author":"Smith","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"R36","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1099\/0022-1317-83-12-2915","article-title":"The formation and function of extracellular enveloped vaccinia virus","volume":"83","author":"Smith","year":"2002","journal-title":"J Gen Virol"},{"key":"R37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0264-410X(98)00197-2","article-title":"Kinetics of formation of neutralizing antibodies against vaccinia virus following re-vaccination","volume":"17","author":"Stienlauf","year":"1999","journal-title":"Vaccine"},{"key":"R38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: a highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"key":"R39","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1016\/j.vaccine.2006.06.006","article-title":"Immune responses to vaccinia and influenza elicited during primary versus recent or distant secondary smallpox vaccination of adults","volume":"24","author":"Treanor","year":"2006","journal-title":"Vaccine"},{"key":"R40","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.vaccine.2006.10.009","article-title":"A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost","volume":"25","author":"Xiao","year":"2007","journal-title":"Vaccine"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.2008\/004440-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T12:41:43Z","timestamp":1604493703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.2008\/004440-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,1]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2008,12,1]]}},"URL":"https:\/\/doi.org\/10.1099\/vir.0.2008\/004440-0","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"value":"0022-1317","type":"print"},{"value":"1465-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,1]]}}}